The global lennox-gastaut syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Lennox-Gastaut syndrome (LGS) is a type of epilepsy that is characterized by frequent and usually daily seizures. The major factor for the growth of the market is the increasing prevalence of LSG across the globe. According to the National Organization for Rare Disorders (NORD), LSG affects males more often than females. It is estimated to occur in .1-.28 people per 100,000. Additionally, it is estimated that it accounts for 1-4% of all cases of childhood epilepsy. Furthermore, it is estimated to occur in 2 per 100,000 children annually. Moreover, it usually occurs between 2-7 years with a peak onset between 3 to 5 years. Hence, the rising prevalence of the disease is driving the demand for LSG drugs which in turn is driving the growth of the market.
To Request a Sample of our Report on Lennox-Gastaut Syndrome Drug Market: https://www.omrglobal.com/request-sample/lennox-gastaut-syndrome-drug-market
Some major players operating in the market include Johnson & Johnson Services, Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2021, Glenmark Pharma announced the launch of the anti-epileptic drug Rufinamide tablets in the US market. Rufinamide tablets are the therapeutic equivalent of Banzel tablets of Eisai, Inc. that is used for the treatment of children with Lennox-Gastaut syndrome.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Drug Type
- By Therapy
- By Route of Administration
- By Distribution Channel
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Johnson & Johnson Services, Inc., and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A full Report of Lennox-Gastaut Syndrome Drug Market is Available @ https://www.omrglobal.com/industry-reports/lennox-gastaut-syndrome-drug-market
Global Lennox-Gastaut Syndrome Drug Market Report by Segment
By Drug Type
- CNS depressants
- Anticonvulsants
- Perampanel
- Cannabidiol
- NRP-2945
- Others
By Therapy
- Medication
- Surgery
- Intravenous Immunoglobulin Therapy
- Ketogenic Diet Products
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Lennox-Gastaut Syndrome Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
